TANDEM DIABETES CARE Reports Revenue Decrease of 2.2%, Net Income Decline of 136.6% for FY2023 Q2

August 27, 2023

☀️Earnings Overview

For the fiscal year 2023 second quarter (ending June 30 2023), TANDEM DIABETES CARE ($NASDAQ:TNDM) reported total revenue of USD 195.9 million and a net income of USD -35.8 million, representing decreases of 2.2% and 136.6%, respectively, compared to the same period the year before.


GoodWhale recently conducted an analysis of the financial and business wellbeing of TANDEM DIABETES CARE, a major player in the diabetes care market. After assessing various aspects, the analysis revealed that TANDEM DIABETES CARE is a high risk investment. This conclusion was based on the Risk Rating, which aggregates data from the income sheet, balance sheet, cashflow statement, and other non-financial sources. GoodWhale has detected four major risk warnings related to the financial and business health of TANDEM DIABETES CARE. These risks can be viewed in more detail if you become a registered user on the GoodWhale website. By doing so, you can get access to further information about TANDEM DIABETES CARE’s financial and business wellbeing. This can help you make more informed decisions about any potential investments. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for TNDM. More…

    Total Revenues Net Income Net Margin
    790.35 -224.47 -22.4%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for TNDM. More…

    Operations Investing Financing
    5.11 0.98 8.73
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for TNDM. More…

    Total Assets Total Liabilities Book Value Per Share
    946.68 617.44 5.06
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for TNDM are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    24.4% -27.4%
    FCF Margin ROE ROA
    -5.2% -40.5% -14.3%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The market for diabetes care products is highly competitive, with major players such as Tandem Diabetes Care Inc, NuVasive Inc, Avanos Medical Inc, and Penumbra Inc vying for market share. While each company has its own strengths and weaknesses, the competition between them is fierce, and it is often the case that one company’s success comes at the expense of its rivals.

    – NuVasive Inc ($NASDAQ:NUVA)

    NuVasive Inc is a medical device company that develops minimally-invasive surgical products and procedures for spine surgery. The company has a market cap of 2.17B as of 2022 and a Return on Equity of -1.33%. NuVasive’s products and procedures are designed to improve patient outcomes and minimize surgical invasiveness. The company’s products are used in a variety of spine surgeries, including lumbar, thoracic, and cervical procedures.

    – Avanos Medical Inc ($NYSE:AVNS)

    Avanos Medical Inc is a medical technology company that focuses on developing and commercializing minimally invasive medical devices. The company has a market cap of 957.63M as of 2022 and a Return on Equity of 2.85%. Avanos’ products are used in a variety of procedures, including pain management, gastrointestinal, urological, ENT, and vascular.

    – Penumbra Inc ($NYSE:PEN)

    As of 2022, Penumbra Inc has a market cap of 6.49B and a Return on Equity of -2.31%. The company is a medical device company that develops, manufactures and markets products for the treatment of neurovascular diseases.


    TANDEM DIABETES CARE has reported a decrease of 2.2% in total revenue and a decrease of 136.6% in net income for the second quarter of FY2023 (ending June 30 2023), compared to the same period last year. Investors should pay close attention to these figures when making investment decisions. They should consider how the company’s performance compares to its competitors, its current financial position, and the potential risks associated with investing in the company before making any investments. Analysts should also consider any potential growth opportunities the company may offer in order to make an informed decision.

    Recent Posts

    Leave a Comment